<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-KEN25013-L0P-FV-DM7"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 S43 IS: Skinny Labels, Big Savings Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-01-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 43</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250109">January 9, 2025</action-date><action-desc><sponsor name-id="S408">Mr. Hickenlooper</sponsor> (for himself, <cosponsor name-id="S422">Mr. Welch</cosponsor>, <cosponsor name-id="S374">Mr. Cotton</cosponsor>, and <cosponsor name-id="S252">Ms. Collins</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSJU00">Committee on the Judiciary</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause"><section section-type="section-one" id="ida07b745196504cbeb2b5816912a07776"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Skinny Labels, Big Savings Act</short-title></quote>.</text></section><section id="idbfb2325609164983ae757e813208cded"><enum>2.</enum><header>Safe harbor from infringement of a method of use patent</header><subsection id="id53902a613f864970805aa5dfd97762c9"><enum>(a)</enum><header>In general</header><text>Section 271 of title 35, United States Code, is amended—</text><paragraph id="id3dcb9bae4c4b4848895d8bf1bb724946"><enum>(1)</enum><text>by redesignating subsections (h) and (i) as subsections (k) and (l), respectively; and</text></paragraph><paragraph id="id2d989cc1965f4ed48b119dbe23ea4430"><enum>(2)</enum><text>by inserting after subsection (g) the following: </text><quoted-block style="OLC" display-inline="no-display-inline" id="idFE79853FC8BB4A948746DE7F0A9430A0"><subsection commented="no" display-inline="no-display-inline" id="id962cf6455f2545a8b8176d041ba005f9"><enum>(h)</enum><paragraph commented="no" display-inline="yes-display-inline" id="id0d6b1c5c10bc45249a817f327409a8fb"><enum>(1)</enum><text display-inline="yes-display-inline">The following shall not be acts of direct, induced, or contributory infringement of a method of use claim in a patent included in the list described in section 505(j)(7) or section 512(n)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(7)</external-xref>, 360b(n)(4)) in an action or counterclaim under this section: </text><subparagraph commented="no" display-inline="no-display-inline" id="id5764640b276a4447a2f1cf6d29b1522c" indent="up1"><enum>(A)</enum><text display-inline="yes-display-inline">Submitting or seeking approval of an application under section 505(j) or section 512(b)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>, 360b(b)(2)), or submitting or seeking approval of an application described in section 505(b)(2) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(2)</external-xref>), provided that such application includes a statement under, as applicable, section 505(j)(2)(A)(viii), section 512(n)(1)(I), or section 505(b)(2)(B) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(2)(A)(viii)</external-xref>, 360b(n)(1)(I), 355(b)(2)(B)) for the method of use claims in the patent with the labeling proposed in such application.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="id24438d884f0a4681a2b9c7bda3fb86c8"><enum>(B)</enum><text display-inline="yes-display-inline">Promoting or commercially marketing a drug product with the labeling approved in an application described in subparagraph (A).</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="idad637ea630a04886976a92788efa1e3c"><enum>(C)</enum><text display-inline="yes-display-inline">Describing a drug product approved in an application submitted under section 505(j) or section 512(b)(2) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)</external-xref>, 360b(b)(2)) or approved in an application described in section 505(b)(2) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)(2)</external-xref>) as a generic of, or therapeutically equivalent to, the listed drug referenced in such application, as applicable.</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" indent="up1" id="id611730aa29354d09bfad17a124a10687"><enum>(2)</enum><text display-inline="yes-display-inline">Subparagraphs (A) through (C) of paragraph (1) shall apply only if the labeling, promotion, or commercial marketing does not reference the condition or conditions of use claimed in the patent that was identified by the patent owner or assignee to the Secretary under section 314.53 of title 21, Code of Federal Regulations (or a successor regulation) and that was subject to the statement under section 505(j)(2)(A)(viii), section 512(n)(1)(I), or section 505(b)(2)(B) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(j)(2)(A)(viii)</external-xref>, 360b(n)(1)(I), 355(b)(2)(B)), as applicable.</text></paragraph></subsection><subsection id="idc1dced963cc641fb81c06ead9af41451"><enum>(i)</enum><paragraph commented="no" display-inline="yes-display-inline" id="id6b5e62cbac844b92bb2f8875122cfe34"><enum>(1)</enum><text>The following shall not be acts of direct, induced, or contributory infringement of a patent claim covering a method of using the reference product in an action or counterclaim under this section:</text><subparagraph commented="no" display-inline="no-display-inline" id="id43fde0e900094f00ab8aa925f55465fe" indent="up1"><enum>(A)</enum><text display-inline="yes-display-inline">Submitting or seeking approval of an application under section 351(k) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(k)</external-xref>).</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="id615fdfa9f8c343f4ac9f7e70682ec850"><enum>(B)</enum><text display-inline="yes-display-inline">Describing a biological product approved in an application described in subparagraph (A) as biosimilar to, or interchangeable with, the reference product, as applicable, with the labeling approved in such application, when the biological product has not been approved for the patented condition or conditions of use.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="id7d962748600f42fa9d945ea5b41377bb"><enum>(C)</enum><text display-inline="yes-display-inline">Promoting or commercially marketing a biological product with the labeling approved in an application described in subparagraph (A).</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" indent="up1" id="id26359909d33440709f64d80de67f71d8"><enum>(2)</enum><text display-inline="yes-display-inline">Subparagraphs (A) through (C) of paragraph (1) shall apply only if the labeling, promotion, or commercial marketing does not reference the condition or conditions of use claimed in the patent and specifically reflected in the prescribing information.</text></paragraph></subsection><subsection commented="no" id="id62f4450b7add4c3c874806f7f0aab8ad"><enum>(j)</enum><text>As used in this section:</text><paragraph commented="no" display-inline="no-display-inline" id="id5155655AD4DE40D0BC8050015D38938F"><enum>(1)</enum><text display-inline="yes-display-inline">The terms <term>biological product</term>, <term>biosimilar</term>, <term>interchangeable</term>, and <term>reference product</term> have the meanings given such terms in section 351(i) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(i)</external-xref>).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="idcda9df966a2b4c5ba1856628d31d55da"><enum>(2)</enum><text display-inline="yes-display-inline">The term <term>commercial marketing</term> has the meaning given such term in section 314.3 of title 21, Code of Federal Regulations (or a successor regulation).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id2f7ba719ebd24c36b15b2b7b8a37f340"><enum>(3)</enum><text display-inline="yes-display-inline">The term <term>labeling</term> has the meaning given such term in section 201(m) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(m)</external-xref>).</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id4a175d6afe694a07b7cd41592b4790c3"><enum>(4)</enum><text display-inline="yes-display-inline">The term <term>promoting</term>—</text><subparagraph commented="no" display-inline="no-display-inline" id="id09d2c99a46e946d88319685e99b0ed24"><enum>(A)</enum><text display-inline="yes-display-inline">is within the meaning of the term used in section 202.1 of title 21, Code of Federal Regulations (or a successor regulation); and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="idc95df0d3835c4d49b61ac3cf8de6f0d2"><enum>(B)</enum><text display-inline="yes-display-inline">includes the use of promotional labeling and advertising, as described in paragraphs (1) and (2) of section 202.1(l) of title 21, Code of Federal Regulations (or successor regulations).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="id0d038c808c664960b752e454e8e7000f"><enum>(b)</enum><header>Application</header><text>This Act and the amendments made by this Act shall apply to—</text><paragraph id="id6c86268695ae4d42b44c94a859425e90"><enum>(1)</enum><text>conduct that occurs before, on, or after the date of enactment of this Act; and</text></paragraph><paragraph id="idcda3de4c1a004af5b20181dc126e9838"><enum>(2)</enum><text>all judicial or other proceedings pending as of such date of enactment.</text></paragraph></subsection></section></legis-body></bill> 

